Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 30.25M P/E - EPS this Y 49.60% Ern Qtrly Grth -
Income -44.6M Forward P/E -0.13 EPS next Y 1.50% 50D Avg Chg -17.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 1.76 EPS next 5Y - 52W High Chg -48.00%
Recommedations 1.00 Quick Ratio 0.66 Shares Outstanding 10.51M 52W Low Chg 225.00%
Insider Own 0.69% ROA -59.57% Shares Float 6.77M Beta 2.47
Inst Own 56.95% ROE -341.98% Shares Shorted/Prior 475.63K/61.06K Price 6.86
Gross Margin - Profit Margin - Avg. Volume 25,833 Target Price 55.00
Oper. Margin - Earnings Date May 7 Volume 7,185 Change -5.25%
About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings News
04/02/24 Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
03/12/24 Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
03/06/24 Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
02/28/24 Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
02/06/24 Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
02/02/24 Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
02/01/24 Retail investors in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) are its biggest bettors, and their bets paid off as stock gained 214% last week
01/31/24 Corbus Pharmaceuticals Announces Pricing of Public Offering
01/30/24 Corbus Pharmaceuticals Announces Proposed Public Offering
01/29/24 Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
01/26/24 CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
01/23/24 Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
01/09/24 Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
12/18/23 Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
12/01/23 Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
11/07/23 Corbus Pharmaceuticals Reports Q3 2023 Financial Results with a Net Loss of $10.1 Million
11/07/23 Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/02/23 Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
07:00 AM Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
10/16/23 Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRBP Chatroom

User Image MGBuckeye Posted - 8 hours ago

$CRBP why

User Image shlomiko Posted - 9 hours ago

$CRBP

User Image shoagh12 Posted - 11 hours ago

$CRBP

User Image shoagh12 Posted - 1 day ago

$CRBP nix the dip

User Image shoagh12 Posted - 1 day ago

$CRBP raise 45 today - target is 55$ soon

User Image CheebasCoco Posted - 1 day ago

$CRBP

User Image Capitulation_0 Posted - 1 day ago

$CRBP I can't believe I missed the dip in the low 30s.. what strength.

User Image shlomiko Posted - 1 day ago

$CRBP

User Image aly2006g Posted - 1 day ago

$CRBP

User Image shoagh12 Posted - 1 day ago

$CRBP

User Image jjk537 Posted - 2 days ago

$CRBP im actually just sitting on this because it’s not worth selling. My break even is 160 per share. Never gonna happen. This dog don’t hunt!

User Image shoagh12 Posted - 2 days ago

$CRBP keep on moving - we raise 45 $ today and than rocket to the moon

User Image PensionPulse Posted - 2 days ago

$CRBP Only biotech trading somewhat nicely. Since dipping recently, it has moved up nicely since March 22 low, trying to make new high..

User Image shoagh12 Posted - 2 days ago

$CRBP 45$ today

User Image vjtweet Posted - 2 days ago

$CRBP there is a decent long chance here. This week's watch list.

User Image ViractaTrader77 Posted - 5 days ago

$BDTX $CRBP Sutro Bio has almost $6 in current assets in cash per share. Big deals with Merck, Vaxcyte, Ispen Pharma and Astellas. And a similar ADC company targeting Folate Receptor with earlier asset just got bought for $1.8 billion. It's the second acquisition in folate receptor first one was Immunogen. Steve Cohen and Ispen Pharma just invested heavily at $5.18 per share. $ELEV $NVDA https://x.com/SutroBio/status/1775949657774112893

User Image shlomiko Posted - 6 days ago

$CRBP

User Image aly2006g Posted - 6 days ago

$CRBP

User Image shoagh12 Posted - 6 days ago

$CRBP 45$ today

User Image shoagh12 Posted - 1 week ago

$CRBP buy the dip - worth about 55$

User Image shlomiko Posted - 1 week ago

$CRBP

User Image shoagh12 Posted - 1 week ago

$CRBP 40$ today

User Image drpower2000 Posted - 1 week ago

@aricray @Multipliers you keep posting about investors so you are telling me that any big investor has a 100% return rate on every investment? If you think that, I have a $1M pet rock I want to sell you. Plain and simple big investor get investments WRONG all the time. The key is to get bigger win than loses. Obviously they expect a return, but it doesn’t mean they will get it. Also they may be satisfied with a 300% return. Where that won’t even get most people on here back to there cost basis. So this is FAR from guaranteed. At this point I give it a 20% odds and that being generous based on most $ARTL $CRBP $GWPH $RVVTF $SKYE tech trial results.

User Image aly2006g Posted - 1 week ago

$CRBP

User Image shoagh12 Posted - 1 week ago

$CRBP

User Image shlomiko Posted - 1 week ago

$CRBP

User Image aly2006g Posted - 1 week ago

$CRBP

User Image BP138 Posted - 1 week ago

$CRBP This thing moves quick.

User Image shoagh12 Posted - 1 week ago

$CRBP 45 today 50 End of the week

User Image Mikeqb20 Posted - 1 week ago

$NRSN #CureALS NEXT 10X BANGER!! Partner is $BIIB NO ALS DRUGS ON MARKET WITH $AMLX FAILURE $NRSN NEXT 10X BANGER $VKTX and $CRBP BOTH 10X PLAYS @RealAvidTrader @jacksparo

Analyst Ratings
Oppenheimer Outperform Mar 13, 24
Jefferies Buy Mar 6, 24
Oppenheimer Outperform Jan 29, 24
Oppenheimer Outperform Aug 9, 23
Oppenheimer Outperform May 10, 23
HC Wainwright & Co. Buy Mar 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
HOLMER ALAN F Director Director Jan 26 Option 4.97 629 3,126 1,379 01/30/24
Cohen Yuval Chief Executive Offi.. Chief Executive Officer Jan 26 Option 4.97 7,179 35,680 7,179 01/30/24
Millian Craig Stuart Chief Operating Offi.. Chief Operating Officer Aug 10 Buy 0.2545 5,000 1,272 27,000 08/12/22
Cohen Yuval Chief Executive Offi.. Chief Executive Officer Aug 10 Buy 0.264 3,800 1,003 98,230 08/11/22
Moran Sean F. Chief Financial Offi.. Chief Financial Officer Aug 10 Buy 0.2599 20,000 5,198 199,272 08/10/22
Moran Sean F. Chief Financial Offi.. Chief Financial Officer May 16 Buy 0.30 12,000 3,600 179,272 05/16/22
Cohen Yuval Chief Executive Offi.. Chief Executive Officer May 16 Buy 0.25 10,500 2,625 94,430 05/16/22
Millian Craig Stuart Chief Operating Offi.. Chief Operating Officer Mar 10 Buy 0.37 10,000 3,700 22,000 03/11/22
Moran Sean F. Chief Financial Offi.. Chief Financial Officer Mar 10 Buy 0.37 15,000 5,550 167,272 03/10/22
Cohen Yuval Chief Executive Offi.. Chief Executive Officer Mar 09 Buy 0.37 8,600 3,182 83,930 03/09/22
Moran Sean F. Chief Financial Offi.. Chief Financial Officer Dec 18 Option 0.17 36,923 6,277 386,533 12/18/20
Moran Sean F. Chief Financial Offi.. Chief Financial Officer Dec 18 Sell 1.32 36,923 48,738 349,610 12/18/20